The BayMedica Platform

At BayMedica we have created an efficient, patent-pending, biochemical manufacturing platform by transforming common brewer’s yeast into a biological factory. We also utilize our expertise in synthetic chemistry to complement our biosynthesis platform. Our synthetic chemistry program has shown that at scale BayMedica cannabinoids have both quality and cost advantages over cannabinoids produced via legacy agriculture.

Harnessing the Power of Cannabinoids

Biosynthesis is a multi-step process where living organisms use enzymes to catalyze the conversion of simple substrates into complex products. Cannabinoids are one class of compounds synthesized by Cannabis, however, the Cannabis sativa plant is an inefficient biological factory for even the most prevalent compounds such as THC and CBD, which typically comprise only 2-5% of the biomass of the plant. Cannabis is even less efficient at synthesizing the 100+ minor cannabinoids like CBC, CBDV and THCV that typically comprise less than 0.1% of plant biomass.

The BayMedica platform solves this issue by engineering common yeast to convert sugar into cannabinoids, including common and rare natural varieties, as well as novel cannabinoid analogs of pharmaceutical interest. We also leverage our experience in synthetic chemistry where applicable. Our cannabinoids have a wide variety of applications in the health and wellness, food and beverage, personal care, cosmetic and pet care industries.

  • Consistent & Pure 100% 100%

Our products are made through a consistent, reproducible process that results in greater purity and consistency than attained by extracting plant material.

  • Regulatory Compliance 100% 100%

Our proprietary platform enables the benefits of cannabis without touching the plant.

  • Rare & Analog Cannabinoids 100% 100%

We can produce common and rare cannabinoid compounds as well as analog compounds not present in the plant.

  • Scalable & Cost Effective 100% 100%

The BayMedica method allows for scalable, cost effective cannabinoid production.

  • Environmentally Friendly 100% 100%

Our method is environmentally sustainable, free of pesticides, fertilizers, mold and heavy metals using enclosed bioreactors.

  • Market Specific Solutions 100% 100%

BayMedica cannabinoids can be tailored for pharmaceutical, nutraceutical, cosmetic, consumer and animal health markets.

Our Biosynthesis Platform & Process


Our team of scientists transforms common brewer’s yeast into a biological factory to produce pure individual bioidentical cannabinoids from simple sugars. Because the process does not involve plant cultivation and extraction, there are no toxic chemicals, pesticides or heavy metals that are commonly found in cannabis and hemp extracts.


After several days of fermentation the yeast turns the sugars into significant quantities of the target cannabinoid.

Using a proprietary process we separate the yeast cells from the broth to prepare for purification of the cannabinoid.

Purification & Concentration

The next step in the process is purifying the cannabinoid from the yeast cell. Unlike extraction of cannabinoids from plants, where toxins, fertilizers and heavy metals can come along for the ride, our proprietary technique gently separates and concentrates the cannabinoid.

Natural & Pure Cannabinoids

The result of step three is pure, natural cannabinoids that are identical to the cannabinoid found in the plant. Unlike traditional extraction methods, our process also allows for the production of rare cannabinoids that are found in tiny quantities in the plant.

These pure cannabinoids are then used to produce consumer products such as cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), and cannabicitran (CBT).

Novel Cannabinoid Analogs

The BayMedica platform also facilitates the production of novel cannabinoid analogs. These compounds are related to naturally occurring cannabinoids, but have been modified to create new chemical entities for novel pharmaceutical development.

Cannabinoid Analogs

Discover the Future of Cannabinoids